TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01737138

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RSD
Description: Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medicine
Description: Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
Study: NCT03408886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral vancomycin is administered to reduce pathogenic bacteria.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MoviPrep
Description: MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota

Intervention type: DRUG
Group type: OTHER
Intervention: MoviPrep
Description: MoviPrep is given at the end of vancomycin therapy to remove the vancomycin and remaining bacteria prior to administering Full-Spectrum Microbiota

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Full Spectrum Microbiota
Description: Gut bacteria from healthy human donors are administered orally in a pill form

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Full Spectrum Microbiota
Description: Gut bacteria from healthy human donors are administered orally in a pill form
Study: NCT01637090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.~Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.~If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded.
Study: NCT00384449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
Study: NCT03019172

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri
Description: Sachet one contains a total of 5\*10\^8 CFU of Lactobacillus reuteri DSM 16666 \& Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be at least 5\*10\^8 CFU of L.reuteri DSM16666 and L. reuteri DSM17938), PAC-A and zinc

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sachet with cranberry + placebo
Description: Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
Study: NCT02389218

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single ablation (CryoBalloonAblation (CBA)
Description: Cryoablation at entry, after randomization to this group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sequential drug adjustment (propafenone, sotalol or flecainide)
Description: Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
Study: NCT01518140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Delivery Devices
Description: Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Delivery Devices
Description: Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen Delivery Devices
Description: Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
Study: NCT01992328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immune Globulin
Description: 6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
Study: NCT03458234

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 16 French Foley Catheter
Description: A Foley catheter is a medical apparatus that creates a passageway for the drainage and collection of urine. This type of catheter is made of a pliable material that indwells into an individual's bladder by way of the urethra.~Featuring two separate channels down the tube, Foley catheters allow absolute stability and safe extraction. One channel of the catheter, by method of a balloon, is stabilized in a bladder; the other channel allows for the passage and collection of urine, by means of a leg bag or bedside drainage bag.~Foley catheters are usually constructed out of either silicone or latex.
Study: NCT02415595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: HIV Maturation Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: HIV Maturation Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-955176
Description: HIV Maturation Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EFV
Description: EFV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: TDF/FTC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: TDF/FTC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Description: TDF/FTC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF/FTC
Description: TDF/FTC
Study: NCT04553978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WD-1603
Description: WD-1603 CARBIDOPA/LEVODOPA EXTENDED-RELEASE TABLETS
Study: NCT02583464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate and emtricitabine
Description: Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate and emtricitabine
Description: Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
Study: NCT03023319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 100mg daily for 4 cycles (21 days per cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 every 21 days for 4 cycles
Study: NCT04168151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lung recruitment protocol
Description: lung recruitment protocol applied to postcardiac surgery hypoxic adult patients with measurement of trans alveolar pressure as an index for lung recruitment
Study: NCT01686347

Intervention type: DRUG
Group type: OTHER
Intervention: ropivacaine

Intervention type: DRUG
Group type: OTHER
Intervention: ropivacaine
Study: NCT02701244

Intervention type: RADIATION
Intervention: Permanent Breast Seed Implant (PBSI)
Description: Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
Study: NCT03944564

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sitting
Description: We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Static standing
Description: We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic standing
Description: We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)
Study: NCT00814021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Study: NCT02148536

Intervention type: PROCEDURE
Intervention: Transjugular intrahepatic portosystemic shunt
Study: NCT03969745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Restrict energy intake window to between 8am and 4pm

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric restriction
Description: Follow a prescribed daily energy deficit of 400 kilocalories without altering nutrient timing
Study: NCT01919073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate Treatment Group
Description: •The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Treatment Group
Description: •The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
Study: NCT04072952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: Parts A and B: ARV-471 administered QD or BID for 28 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471 in combination with palbociclib (IBRANCE®)
Description: Part C: Daily oral dosages of ARV-471 for 28 days in combination with palbociclib (IBRANCE®) for 21 days
Study: NCT04852549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oculomotor exercise
Description: 1. While holding the head in the middle position, holding two colored objects in both hands, looking at the object in the right hand without turning the head, counting up to 10 and looking at the object in the left hand and counting up to 10,~2. While holding a fixed head in the middle position and holding a colored object in the right hand, following the object with the eyes while moving the right hand from right to left without turning the head and returning,~3. With the head fixed in the middle position, with the right hand on the left, eyes are fixed on the hand-held colored object and turn the head to the right and left.~4. The head will be fixed in the middle position, the eyes will be fixed on the colored object held in the right or left hand and the arm and the head will be turned to opposite directions.
Study: NCT02096250

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaFeEDTA

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ferrous fumarate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NaFeEDTA + ferrous fumarate
Study: NCT01601756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: navigated revision knee arthroplasty
Description: revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional revision knee arthroplasty
Description: revision knee arthroplasty using conventional instruments
Study: NCT01504516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: Donepezil Hydrochloride Tablets 10 mg
Study: NCT01395966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF289
Description: Ear drops
Study: NCT01504516

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept
Description: Aricept 10 mg Tablets
Study: NCT03870373

Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: Aulisa's non-invasive pulse oximeter sensor is applied to a foot of the neonate; an adhesive patch secures the sensor to the neonate.
Study: NCT01781806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200mg/tenofovir 300mg
Description: The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine 200mg/tenofovir 300mg
Description: The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in creatinine clearance (CrCl) to \<50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with CrCl \<30 mL/min, Truvada will be discontinued.
Study: NCT03528122

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Recurrent opened macular hole
Description: pars plana vitrectomy + internal limiting membrane peeling + Amniotic membrane graft placement over the hole + intraocular tamponade
Study: NCT03815630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pd-1 and dc-cik cells
Description: Total dose of 10ml Keytruda will be administered at day0, 60million DC cells and 1.5 billion CIK at day1, 1.5 billion CIK cells at day2, 1.5 billion CIK cells at day3 .
Study: NCT01026090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronedarone
Description: Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for dronedarone)
Description: film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Study: NCT01967797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5As Team Intervention
Description: The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes \& team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners \& teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
Study: NCT02250131

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Perfusion targeted at oxygen delivery
Description: Flow on cardiopulmonary bypass based on a target oxygen delivery \> 280 mL/min/m2
Study: NCT00617097

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: paracervical block with lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketorolac and lidocaine
Description: paracervical block with ketorolac and lidocaine
Study: NCT03060993

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis
Description: Patients will be administered cannabis (THC/CBD) in vaporized form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
Study: NCT02575872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in physical activity behavioral intervention
Study: NCT05195086

Intervention type: DRUG
Intervention: endoxan
Description: Immunosuppressant

Intervention type: DRUG
Intervention: cellcept
Description: Immunosuppressant
Study: NCT01389726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Parent Training
Description: Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial-Informational support
Description: Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader \& 1 peer leader over the course of 11 weeks.
Study: NCT02383186

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermal Suturing Only Wound Closure
Description: The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermal Suturing Only Wound Closure
Description: The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Layered Cutaneous Wound Closure
Description: The side assigned to layered closure is closed with 5-0 fast acting gut.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Layered Cutaneous Wound Closure
Description: The side assigned to layered closure is closed with 5-0 fast acting gut.
Study: NCT01151384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LE-DT
Description: Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
Study: NCT04993248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialog Circle
Description: The intervention will offer participants the opportunity to share feelings and needs with people who are in a similar situation to their own.~Each intervention consists of 3 dialogue circles per group. Each group is composed of 10 participants and a facilitator, in all interventions the facilitator will be the principal investigator.
Study: NCT01395966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DF277
Description: Ear drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DF289 plus DF277
Description: Ear drops